Deals this week: HalioDx SAS, Hologic, Siemens Healthcare GmbH

19 January 2018 (Last Updated January 19th, 2018 09:53)

French-based diagnostics company HalioDx SAS has raised €18.5m ($22.65m) through a Series B funding round led by the Private Sector Investment Management (PSIM) fund.

French-based diagnostics company HalioDx SAS has raised €18.5m ($22.65m) through a Series B funding round led by the Private Sector Investment Management (PSIM) fund.

HalioDx has developed an immune biomarker partnering programme with Biopharma to assess and predict the value of Immunoscore and other proprietary assays.

The company plans to use part of the funds for the development of Immunoscore tool for colon and other select cancer types.

The remaining funds will be used to set up commercial activities in the US.

US-based company Hologic Inc has announced the pricing for its proposed $600m private placement of 4.375% senior notes.

The notes are due in 2025 and will be issued at a price of $1,000 each.

The company has simultaneously priced a $400m private placement of 4.625% senior notes.

Due 2028, the notes will be issued at a price of $1,000 each.

The proceeds are intended to be used for the redemption of the company’s outstanding 5.25% senior notes due in 2022 for an aggregate principal amount of $1bn.

“Tissue Analytics plans to use the funds for increasing the size of its sales team in the Kansas City office and recruiting data analytics staff in the Baltimore office.”

Siemens Healthcare GmbH plans for an initial public offering of shares to raise funds.

Based in Germany, Siemens Healthcare is a medical technology and healthcare company that is a subsidiary of Siemens AG.

Obalon Therapeutics Inc has announced a public offering of shares of its common stock to raise $35m in gross proceeds. Underwriters will be granted an option to purchase additional shares worth $5.25m within 30 days.

The US-based company plans to use the funds for the ongoing commercialisation of its weight loss balloon system and for other corporate purposes.

Immunodiagnostic Systems Holdings Plc has entered an agreement to globally enable it to sell Technogenetics srl’s range of assay kits under the Immunodiagnostic brand.

The ten-year agreement gives Immunodiagnostic the right to obtain the necessary regulatory approvals to sell the assay kits under its brand and market them worldwide.

Based in the UK, Immunodiagnostic Systems is a provider of automated and manual diagnostic testing kits, whereas Technogenetics is a medical diagnostics company based in Italy.

US-based mobile application software developer, Tissue Analytics Inc has raised $5m through a Series A financing round led by local investment company DigiTx Partners LLC.

Tissue Analytics plans to use the funds for increasing the size of its sales team in the Kansas City office and recruiting data analytics staff in the Baltimore office.